[Chinese guidelines on clinical application of antiphospholipid antibodies (2026 edition)].

Antiphospholipid antibodies (aPLs) are a group of autoantibodies that target phospholipids and/or phospholipid-binding proteins. aPLs are serum markers for antiphospholipid syndrome (APS) and are crucial indicators for predicting risks and managing anticoagulant therapy in APS and aPLs related diseases. Developing clinical guidelines for aPLs in China can further standardize laboratory testing and improve the ability to interpret results, thereby playing a critical role in enhancing the diagnostic, treatment, and management capabilities of clinicians involved in APS. National Clinical Research Center for Rheumatic and Autoimmune Diseases, collaborating with Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, China Rheumatism Data Center, Chinese Systemic Lupus Erythematosus Treatment and Research Group, strictly adhering to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system and the reporting items for practice guidelines in Healthcare (RIGHT) checklists. This guideline includes 10 recommendations on the clinical application of aPLs, aiming to standardize their clinical use and laboratory testing, and to provide references for the clinical diagnosis, treatment, and management of APS and aPLs related diseases.